Table 2 Unique UPRs induced by CPA in GL261(B6) compared to LLC and B16F10 tumors. Shown are the 47 UPRs unique to CPA-treated GL261(B6) tumors identified in Additional file 4: Table S3G, classified into 4 categories based on their functions. Group 1 UPRs are expected to contribute to the anti-tumor response, group 2 UPRs counter the anti-tumor response, and the actions of group 3 UPRs depend on cell context. Only two of the UPRs are associated with the glioma-specific lineage of GL261 tumors (group 4)
Category | Reported function | Predicted activation state | Molecule type | Upstream regulator |
|---|---|---|---|---|
1. Facilitate tumor regression by immune-mediated mechanisms or by inhibiting tumor cell survival | Activate immune responses | Activated | Cytokine | IL12 (complex), IL7,IL12A,IL12B,CCL11 |
Enzyme | TRAF6 | |||
Kinase | MAPK8,MAPKAPK2,MAP3K14,RIPK2 | |||
Other | MOG,TAC1 | |||
Transcription regulator | TBX21,HMGB1,IRF6,HOXA7 | |||
Transmembrane receptor | TLR2,TYROBP,CD2,CD14,OLR1,CD86,BTNL2 | |||
Inhibit immune responses | Inhibited | Transcription regulator | PRDM1 | |
Neurohormone | CORT | |||
Phosphatase | DUSP1 | |||
Promote tumor cell survival | Inhibited | Enzyme | SCD | |
Growth factor | WISP2 | |||
Kinase | PRKAA1 | |||
Mature microRNA | miR-155-5p (miRNAs w/seed UAAUGCU) | |||
Transcription regulator | MAX,BCL3 | |||
2. Counter tumor regression | Inhibit immune respones | Activated | Enzyme | PTGS2 |
Promote tumor cell survival | Activated | Enzyme | FN1 | |
Kinase | FGFR2 | |||
3. Postive or negatve regulator of immune response, depending on cell context | Activate or inhibit immunity | Activated | Cytokine | CSF2,CXCL8,PF4 |
G-protein coupled receptor | CCR5 | |||
Apoptotic factor | TRADD | |||
Activate or inhibit immunity | Inhibited | Enzyme | TAB1 | |
Kinase | MTOR | |||
Other | PTX3 | |||
Transcription regulator | IRF4 | |||
Transporter | APOA1 | |||
4. Glioma cell lineage | Brain development | Activated | Transcription regulator | SIM1,PAX7 |